Therapeutic vaccines for cancer: an overview of clinical trials

By I. Melero, G. Gaudernack, W. Gerritsen, C. Huber, G. Parmiani, S. Scholl, N. Thatcher, J. Wagstaff, C. Zielinski, Ian Faulkner and 1 more. Nature Reviews Clinical Oncology, 2014

724 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/32f6132f0c9b35f9915b2c492a59a7dbc5d401f9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. S. Farkona
2. Eleftherios P. Diamandis
3. I. Blasutig
4. Padmanee Sharma
5. James P. Allison

In Molecular Biology

1. Eleftherios P. Diamandis
2. Andrew Emili
3. Jennifer Listgarten

In Oncology

1. Eleftherios P. Diamandis
2. S. Farkona
3. I. Blasutig
4. Padmanee Sharma
5. James P. Allison

Citations in the corpus

• Current Challenges in Cancer Treatment. (2016, background): “There are comprehensive reviews in the field, which we recommend for interested readers.(36) As far as passive immunotherapies are concerned, adoptive T-cell therapy is among the most exciting anticancer immunotherapy.”
• Therapeutic cancer vaccines. (2010, background): “A recent review has detailed clinical therapeutic vaccination studies in patients with nonviral cancers (1).”
• Immune Checkpoint Targeting in Cancer Therapy: Towards Combination Strategies with Curative Potential (2015, background): “Many reasons might have contributed to the failure of these vaccination strategies, including choice of antigen, failure to provide adequate costimulation, or functional inactivation of tumorreactive T cells (Melero et al., 2014).”
• Cancer immunotherapy: the beginning of the end of cancer? (2016, background): “trials [11, 142], this approach has not yet flourished.”